| molecular function |
|---|
| | GO:0005179 | | hormone activity | | The action characteristic of a hormone, any substance formed in very small amounts in one specialized organ or group of cells and carried (sometimes in the bloodstream) to another organ or group of cells in the same organism, upon which it has a specific regulatory action. The term was originally applied to agents with a stimulatory physiological action in vertebrate animals (as opposed to a chalone, which has a depressant action). Usage is now extended to regulatory compounds in lower animals and plants, and to synthetic substances having comparable effects; all bind receptors and trigger some biological process. |
| | GO:0005184 | | neuropeptide hormone activity | | The action characteristic of a neuropeptide hormone, any peptide hormone that acts in the central nervous system. A neuropeptide is any of several types of molecules found in brain tissue, composed of short chains of amino acids; they include endorphins, enkephalins, vasopressin, and others. They are often localized in axon terminals at synapses and are classified as putative neurotransmitters, although some are also hormones. |
| | GO:0071855 | | neuropeptide receptor binding | | Interacting selectively and non-covalently with a neuropeptide receptor. |
| | GO:0051428 | | peptide hormone receptor binding | | Interacting selectively and non-covalently with a receptor for peptide hormones. |
| | GO:0005515 | | protein binding | | Interacting selectively and non-covalently with any protein or protein complex (a complex of two or more proteins that may include other nonprotein molecules). |
| | GO:0005102 | | receptor binding | | Interacting selectively and non-covalently with one or more specific sites on a receptor molecule, a macromolecule that undergoes combination with a hormone, neurotransmitter, drug or intracellular messenger to initiate a change in cell function. |
| biological process |
|---|
| | GO:0006182 | | cGMP biosynthetic process | | The chemical reactions and pathways resulting in the formation of cyclic GMP, guanosine 3',5'-phosphate. |
| | GO:0014898 | | cardiac muscle hypertrophy in response to stress | | The physiological enlargement or overgrowth of all or part of the heart muscle due to an increase in size (not length) of individual cardiac muscle fibers, without cell division, as a result of a disturbance in organismal or cellular homeostasis. |
| | GO:0061049 | | cell growth involved in cardiac muscle cell development | | The growth of a cardiac muscle cell, where growth contributes to the progression of the cell over time from its initial formation to its mature state. |
| | GO:0044267 | | cellular protein metabolic process | | The chemical reactions and pathways involving a specific protein, rather than of proteins in general, occurring at the level of an individual cell. Includes cellular protein modification. |
| | GO:0071260 | | cellular response to mechanical stimulus | | Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a mechanical stimulus. |
| | GO:0007565 | | female pregnancy | | The set of physiological processes that allow an embryo or foetus to develop within the body of a female animal. It covers the time from fertilization of a female ovum by a male spermatozoon until birth. |
| | GO:0030308 | | negative regulation of cell growth | | Any process that stops, prevents, or reduces the frequency, rate, extent or direction of cell growth. |
| | GO:1903815 | | negative regulation of collecting lymphatic vessel constriction | | Any process that stops, prevents or reduces the frequency, rate or extent of collecting lymphatic vessel constriction. |
| | GO:0003085 | | negative regulation of systemic arterial blood pressure | | The process that reduces the force with which blood travels through the systemic arterial circulatory system. |
| | GO:0007218 | | neuropeptide signaling pathway | | The series of molecular signals generated as a consequence of a peptide neurotransmitter binding to a cell surface receptor. |
| | GO:0060452 | | positive regulation of cardiac muscle contraction | | Any process that increases the frequency, rate or extent of cardiac muscle contraction. |
| | GO:1902261 | | positive regulation of delayed rectifier potassium channel activity | | Any process that activates or increases the frequency, rate or extent of delayed rectifier potassium channel activity. |
| | GO:0010460 | | positive regulation of heart rate | | Any process that activates or increases the frequency or rate of heart contraction. |
| | GO:1903766 | | positive regulation of potassium ion export across plasma membrane | | Any process that activates or increases the frequency, rate or extent of potassium ion export across plasma membrane. |
| | GO:0007168 | | receptor guanylyl cyclase signaling pathway | | A series of molecular signals initiated by the binding of an extracellular ligand to a receptor on the surface of the target cell where the receptor possesses guanylyl cyclase activity, and ending with regulation of a downstream cellular process, e.g. transcription. |
| | GO:0060372 | | regulation of atrial cardiac muscle cell membrane repolarization | | Any process that modulates the establishment or extent of a membrane potential in the polarizing direction towards the resting potential in an atrial cardiomyocyte. |
| | GO:0008217 | | regulation of blood pressure | | Any process that modulates the force with which blood travels through the circulatory system. The process is controlled by a balance of processes that increase pressure and decrease pressure. |
| | GO:0050880 | | regulation of blood vessel size | | Any process that modulates the size of blood vessels. |
| | GO:1902514 | | regulation of calcium ion transmembrane transport via high voltage-gated calcium channel | | Any process that modulates the frequency, rate or extent of generation of calcium ion transmembrane transport via high voltage-gated calcium channel. |
| | GO:1903779 | | regulation of cardiac conduction | | Any process that modulates the frequency, rate or extent of cardiac conduction. |
| | GO:1901841 | | regulation of high voltage-gated calcium channel activity | | Any process that modulates the frequency, rate or extent of high voltage-gated calcium channel activity. |
| | GO:0001666 | | response to hypoxia | | Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus indicating lowered oxygen tension. Hypoxia, defined as a decline in O2 levels below normoxic levels of 20.8 - 20.95%, results in metabolic adaptation at both the cellular and organismal level. |
| | GO:0032868 | | response to insulin | | Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an insulin stimulus. Insulin is a polypeptide hormone produced by the islets of Langerhans of the pancreas in mammals, and by the homologous organs of other organisms. |
| | GO:0035994 | | response to muscle stretch | | Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a myofibril being extended beyond its slack length. |
| | GO:0006367 | | transcription initiation from RNA polymerase II promoter | | Any process involved in the assembly of the RNA polymerase II preinitiation complex (PIC) at an RNA polymerase II promoter region of a DNA template, resulting in the subsequent synthesis of RNA from that promoter. The initiation phase includes PIC assembly and the formation of the first few bonds in the RNA chain, including abortive initiation, which occurs when the first few nucleotides are repeatedly synthesized and then released. Promoter clearance, or release, is the transition between the initiation and elongation phases of transcription. |
| cellular component |
|---|
| | GO:0005737 | | cytoplasm | | All of the contents of a cell excluding the plasma membrane and nucleus, but including other subcellular structures. |
| | GO:0005576 | | extracellular region | | The space external to the outermost structure of a cell. For cells without external protective or external encapsulating structures this refers to space outside of the plasma membrane. This term covers the host cell environment outside an intracellular parasite. |
| | GO:0005615 | | extracellular space | | That part of a multicellular organism outside the cells proper, usually taken to be outside the plasma membranes, and occupied by fluid. |
| | GO:0042629 | | mast cell granule | | Coarse, bluish-black staining cytoplasmic granules, bounded by a plasma membrane and found in mast cells and basophils. Contents include histamine, heparin, chondroitin sulfates, chymase and tryptase. |
| | GO:0005634 | | nucleus | | A membrane-bounded organelle of eukaryotic cells in which chromosomes are housed and replicated. In most cells, the nucleus contains all of the cell's chromosomes except the organellar chromosomes, and is the site of RNA synthesis and processing. In some species, or in specialized cell types, RNA metabolism or DNA replication may be absent. |
| | GO:0048471 | | perinuclear region of cytoplasm | | Cytoplasm situated near, or occurring around, the nucleus. |
Description
